A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.

Document Type

Conference Proceeding

Publication Date

1-11-2026

Publication Title

Journal of Clinical Oncology

First Page

TPS273

Last Page

TPS273

Volume

44

Publisher

American Society of Clinical Oncology

Rights

Copyright © 2026 by the American Society of Clinical Oncology

Share

COinS